Biostage, Inc. (BSTG) ended last trading session with a change of 8.85 percent. It trades at an average volume of 1.33M shares versus 4.31M shares recorded at the end of last trading session. The share price of $0.39 is at a distance of 32 percent from its 52-week low and down -86.5 percent versus its peak. The company has a market cap of $14.14M and currently has 36.62M shares outstanding. The share price is currently 8.15 percent versus its SMA20, -38.08 percent versus its SMA50, and -58.28 percent versus its SMA200. The stock has a weekly performance of -4.17 percent and is -56.62 percent year-to-date as of the recent close.
Feb. 16, 2017 — Biostage, Inc. (BSTG) a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the esophagus, bronchus and trachea, announced the closing on February 15, 2017 of its previously announced public offering of 20,000,000 shares of common stock and warrants to purchase 20,000,000 shares of common stock, for total gross proceeds of $8.0 million. The offering was priced at $0.40 per share of common stock, with each share of common stock sold with one five-year warrant to purchase one share of common stock, at an exercise price of $0.40 per share.
Incyte Corporation (INCY) recently recorded 1.2 percent change and currently at $151.03 is 150.46 percent away from its 52-week low and down 0.41 percent versus its peak. It has a past 5-day performance of 12.39 percent and trades at an average volume of 2.22M shares. The stock has a 1-month performance of 22.83 percent and is 50.62 percent year-to-date as of the recent close. There were about 188.6M shares outstanding which made its market cap $28.48B. The share price is currently 16.82 percent versus its SMA20, 24.89 percent versus its SMA50, and 55.83 percent versus its SMA200.
March 2, 2017 — Incyte Corporation (INCY) announces that 20 abstracts from its research and development portfolio will be presented at the upcoming 2017 American Association for Cancer Research (AACR) annual meeting in Washington, D.C. from April 1-5, 2017. These abstracts include a clinical data presentation from the dose-escalation phase of the Company’s ongoing trial of its selective FGFR 1/2/3 inhibitor (INCB54828), and well as preclinical data from its small molecule inhibitor programs targeting PI3Kδ (INCB50465), LSD1 (INCB59872), JAK1 (INCB52793), BRD/BET (INCB54329 and INCB57643) and FGFR4 (INCB62079) and from its epacadostat, OX40 (INCAGN1949) and GITR (INCAGN1876) immuno-oncology programs.